Northwestern Mutual Wealth Management Co. Makes New Investment in Edwards Lifesciences Corporation $EW

Northwestern Mutual Wealth Management Co. bought a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) in the second quarter, Holdings Channel reports. The fund bought 47,155 shares of the medical research company’s stock, valued at approximately $4,266,000.

Several other large investors have also recently made changes to their positions in the business. Hanson & Doremus Investment Management purchased a new stake in shares of Edwards Lifesciences in the 1st quarter worth approximately $25,000. JPL Wealth Management LLC bought a new position in Edwards Lifesciences during the 3rd quarter valued at approximately $25,000. MV Capital Management Inc. purchased a new position in Edwards Lifesciences during the fourth quarter valued at $26,000. RMG Wealth Management LLC purchased a new position in Edwards Lifesciences during the first quarter valued at $26,000. Finally, TrinityBridge Ltd bought a new stake in Edwards Lifesciences in the second quarter worth $27,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 568 shares of the business’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the sale, the senior vice president directly owned 15,334 shares in the company, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the transaction, the vice president directly owned 40,034 shares in the company, valued at $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 25,570 shares of company stock worth $2,219,390. 0.31% of the stock is owned by insiders.

Edwards Lifesciences Price Performance

EW opened at $89.89 on Monday. The company’s 50-day simple moving average is $89.21 and its two-hundred day simple moving average is $84.68. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The stock has a market capitalization of $51.76 billion, a P/E ratio of 51.66, a P/E/G ratio of 2.25 and a beta of 0.85. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same period in the previous year, the business posted $0.67 earnings per share. The business’s revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on EW. Wall Street Zen cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Evercore reaffirmed an “outperform” rating and issued a $100.00 price target on shares of Edwards Lifesciences in a research report on Monday, July 6th. Piper Sandler reiterated an “overweight” rating and issued a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. Truist Financial increased their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. Finally, Royal Bank Of Canada raised their price objective on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.